# Eton Pharmaceuticals (ETON) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ETON
## Company Profile
- Ticker: ETON
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Rare Disease
## Stock Data
- Close: 54.75 USD
- Market cap: 750550609.1999999 USD
- Last updated: 2026-10-08
## Business Overview
### Rare Disease Commercialization Company
Eton Pharmaceuticals develops and commercializes treatments for rare diseases. Its portfolio includes ten commercial products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
### Expanding Commercial Portfolio
During 2026, Eton received FDA approval for and launched DESMODA, while also acquiring and relaunching HEMANGEOL. The Eton Cares support platform and rare-disease distribution model are intended to improve access and adherence.
### Acquisition and Licensing Model
Eton builds its portfolio by acquiring or licensing products that can be commercialized through a focused rare-disease infrastructure. This allows the company to add approved products and late-stage candidates without relying solely on internally discovered assets.
### Late-Stage Pipeline
The company has four late-stage candidates: Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. Additional work includes a KHINDIVI label expansion, extended-release zinc acetate candidate ET-700, and label harmonization for INCRELEX.
### Rare Disease Patient Support
Eton Cares provides reimbursement assistance, product access, and adherence support across the portfolio. A shared patient-services infrastructure allows newly acquired products to be integrated into the company’s existing rare-disease commercial organization.
## Why The Stock Is Moving

As of Oct 8, 2026, ETON was little changed and closed at $54.75. No new same-company headline was identified in the current news window.

## Future Catalysts

- Commercial launch of IMPAVIDO in September 2026.
- Submission of an NDA for AMGLIDIA by the end of 2026.
- First-patient dosing in the INCRELEX label-harmonization study by the end of 2026.
- Potential FDA approval of the expanded KHINDIVI indication in the first half of 2027.
- Initiation of a pivotal study of ET-700 in early 2027, subject to supportive pilot results.
- Submission of an NDA for ASN-001 in the second half of 2027.

## Recent News
- 2026-09-28 10:50 EST — [Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules](https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-u-s-commercial-availability-of-impavido-miltefosi-a43e7fef) — Source: Eton Pharmaceuticals
- 2026-08-27 10:50 EST — [Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference](https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-participate-at-2026-wells-fargo-healthcare-conference-6afc439c) — Source: Eton Pharmaceuticals
- 2026-08-13 20:05 EST — [Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2026-financial-results-a15ca71e) — Source: Eton Pharmaceuticals
- 2026-08-05 10:50 EST — [Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001](https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-expands-infantile-hemangioma-franchise-with-acquisition-of--8893e69c) — Source: Eton Pharmaceuticals
- 2026-08-03 10:50 EST — [Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026](https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-thursday-e5252f95) — Source: Eton Pharmaceuticals